SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

Summary

This will be a placebo-controlled, randomized, double blind, crossover study with a 4 week wash out period. Collect pilot data on the safety, tolerability, and feasibility of empagliflozin therapy in overweight/obese patients with CFRD to support a future larger randomized controlled trial.

Timeline

Start

2024-01-08

Primary completion

2025-06-03

Completion

2026-12-31

Drugs

Indications